Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS ALT5 Sigma	$8.70 -7.2%	$7.69	$1.29 ▼ $10.95	$163.73M	2.31	230,535 shs	434,578 shs
CASI CASI Pharmaceuticals	$1.30 +0.4%	$1.80	$1.10 ▼ $7.67	$15.93M	0.66	89,220 shs	36,545 shs
KYTX Kyverna Therapeutics	$3.47 +13.0%	$2.54	$1.78 ▼ $11.40	$132.68M	2.52	380,326 shs	852,400 shs
TIL Instil Bio	$22.17 -17.6%	$22.28	$9.62 ▼ $92.00	$176.50M	2.27	182,640 shs	565,969 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS ALT5 Sigma	-7.25%	-5.02%	-2.90%	+110.65%	+869,999,900.00%
CASI CASI Pharmaceuticals	+0.39%	-4.41%	-31.22%	-39.68%	-63.59%
KYTX Kyverna Therapeutics	+13.03%	+19.24%	+34.50%	+73.50%	-52.27%
TIL Instil Bio	-17.61%	-22.43%	-8.39%	+22.62%	+128.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS ALT5 Sigma	0.1862 of 5 stars	0.0	3.0	0.0	1.8	0.0	0.0
CASI CASI Pharmaceuticals	4.3094 of 5 stars	3.5	3.0	4.3	4.4	1.7	0.0
KYTX Kyverna Therapeutics	2.9849 of 5 stars	3.6	3.0	0.0	3.3	1.7	0.6
TIL Instil Bio	3.2272 of 5 stars	3.5	2.0	0.0	2.5	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	207.69% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	433.14% Upside
TIL Instil Bio	3.00	Buy	$119.00	436.76% Upside

Current Analyst Ratings Breakdown

Latest CASI, ALTS, TIL, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS ALT5 Sigma	$12.53M	12.12	N/A	N/A	$0.49 per share	17.76
CASI CASI Pharmaceuticals	$28.54M	0.56	N/A	N/A	$0.12 per share	10.83
KYTX Kyverna Therapeutics	$7.03M	21.33	N/A	N/A	$6.17 per share	0.56
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-38.58%	-113.79%	-8.96%	N/A
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-45.52%	-29.23%	8/12/2025 (Estimated)

Latest CASI, ALTS, TIL, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A
3/31/2025	Q4 2024	CASI CASI Pharmaceuticals	-$0.60	-$0.79	-$0.19	-$0.79	$7.39 million	$13.36 million
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS ALT5 Sigma	1.26	0.83	0.83
CASI CASI Pharmaceuticals	N/A	0.81	0.68
KYTX Kyverna Therapeutics	N/A	7.44	7.44
TIL Instil Bio	0.58	30.33	30.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS ALT5 Sigma	6.27%
CASI CASI Pharmaceuticals	22.23%
KYTX Kyverna Therapeutics	18.08%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
ALTS ALT5 Sigma	4.90%
CASI CASI Pharmaceuticals	21.24%
KYTX Kyverna Therapeutics	22.00%
TIL Instil Bio	47.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS ALT5 Sigma	170	17.45 million	16.60 million	N/A
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	33.71 million	Optionable
TIL Instil Bio	410	6.56 million	3.46 million	No Data

CASI, ALTS, TIL, and KYTX Headlines

Recent News About These Companies

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development

June 2, 2025 | quiverquant.comQ

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

June 2, 2025 | globenewswire.com

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025 | globenewswire.com

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

May 29, 2025 | zacks.com

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

May 29, 2025 | zacks.com

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 25, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...

May 25, 2025 | morningstar.comM

Instil Bio stock price target cut to $105 by H.C. Wainwright

May 24, 2025 | uk.investing.com

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in ...

May 24, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 23, 2025 | globenewswire.com

Instil Bio Shares Jump on Trial Updates for Lung Cancer Treatment

May 23, 2025 | marketwatch.com

Instil Bio shares rise after updates on cancer trials

May 23, 2025 | seekingalpha.com

Instil Bio shares rise on immunotherapy trial updates

May 23, 2025 | msn.com

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 22, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
By Leo Miller | June 3, 2025
View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Breakout Momentum Plays You May Not Know About
By Nathan Reiff | June 6, 2025
View Breakout Momentum Plays You May Not Know About
SoundHound’s AI Growth Story Is Just Getting Started
By Gabriel Osorio-Mazilli | June 16, 2025
View SoundHound’s AI Growth Story Is Just Getting Started

CASI, ALTS, TIL, and KYTX Company Descriptions

ALT5 Sigma NASDAQ:ALTS

$8.70 -0.68 (-7.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$8.80 +0.10 (+1.09%)

As of 06/26/2025 07:56 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

CASI Pharmaceuticals NASDAQ:CASI

$1.30 +0.01 (+0.39%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$1.26 -0.04 (-3.15%)

As of 06/26/2025 07:55 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Kyverna Therapeutics NASDAQ:KYTX

$3.47 +0.40 (+13.03%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.56 +0.09 (+2.59%)

As of 06/26/2025 07:17 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Instil Bio NASDAQ:TIL

$22.17 -4.74 (-17.61%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$22.10 -0.07 (-0.32%)

As of 04:47 AM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time